Cargando…

Understanding Inborn Errors of Metabolism through Metabolomics

Inborn errors of metabolism (IEMs) are rare diseases caused by a defect in a single enzyme, co-factor, or transport protein. For most IEMs, no effective treatment is available and the exact disease mechanism is unknown. The application of metabolomics and, more specifically, tracer metabolomics in I...

Descripción completa

Detalles Bibliográficos
Autores principales: Driesen, Karen, Witters, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143820/
https://www.ncbi.nlm.nih.gov/pubmed/35629902
http://dx.doi.org/10.3390/metabo12050398
_version_ 1784715899424473088
author Driesen, Karen
Witters, Peter
author_facet Driesen, Karen
Witters, Peter
author_sort Driesen, Karen
collection PubMed
description Inborn errors of metabolism (IEMs) are rare diseases caused by a defect in a single enzyme, co-factor, or transport protein. For most IEMs, no effective treatment is available and the exact disease mechanism is unknown. The application of metabolomics and, more specifically, tracer metabolomics in IEM research can help to elucidate these disease mechanisms and hence direct novel therapeutic interventions. In this review, we will describe the different approaches to metabolomics in IEM research. We will discuss the strengths and weaknesses of the different sample types that can be used (biofluids, tissues or cells from model organisms; modified cell lines; and patient fibroblasts) and when each of them is appropriate to use.
format Online
Article
Text
id pubmed-9143820
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91438202022-05-29 Understanding Inborn Errors of Metabolism through Metabolomics Driesen, Karen Witters, Peter Metabolites Review Inborn errors of metabolism (IEMs) are rare diseases caused by a defect in a single enzyme, co-factor, or transport protein. For most IEMs, no effective treatment is available and the exact disease mechanism is unknown. The application of metabolomics and, more specifically, tracer metabolomics in IEM research can help to elucidate these disease mechanisms and hence direct novel therapeutic interventions. In this review, we will describe the different approaches to metabolomics in IEM research. We will discuss the strengths and weaknesses of the different sample types that can be used (biofluids, tissues or cells from model organisms; modified cell lines; and patient fibroblasts) and when each of them is appropriate to use. MDPI 2022-04-27 /pmc/articles/PMC9143820/ /pubmed/35629902 http://dx.doi.org/10.3390/metabo12050398 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Driesen, Karen
Witters, Peter
Understanding Inborn Errors of Metabolism through Metabolomics
title Understanding Inborn Errors of Metabolism through Metabolomics
title_full Understanding Inborn Errors of Metabolism through Metabolomics
title_fullStr Understanding Inborn Errors of Metabolism through Metabolomics
title_full_unstemmed Understanding Inborn Errors of Metabolism through Metabolomics
title_short Understanding Inborn Errors of Metabolism through Metabolomics
title_sort understanding inborn errors of metabolism through metabolomics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143820/
https://www.ncbi.nlm.nih.gov/pubmed/35629902
http://dx.doi.org/10.3390/metabo12050398
work_keys_str_mv AT driesenkaren understandinginbornerrorsofmetabolismthroughmetabolomics
AT witterspeter understandinginbornerrorsofmetabolismthroughmetabolomics